Biofortuna genotyping and phenotyping products: Better by Design.
Biofortuna Ltd is a molecular diagnostics company creating solutions to make complex genotyping and phenotyping easier. Biofortuna products are better by design, resulting in diagnostic tests that are more accurate, quicker, easier, and more cost effective than comparable kits: in other words, Biofortuna products are better by design.
Our first product families, HLA and ABO genotyping, are targeted for the transplantation and haematology markets. We are developing a range of unique diagnostic solutions which will offer significant advantages in terms of speed, resolution and ease-of-use to our customers. We will provide products for clinical laboratories, research centres and point-of-care customers.
We manufacture to ISO 9001:2000 and ISO 13485 standards. All products manufactured for In Vitro Diagnostic use will carry the CE mark for compliance with the EU In Vitro Diagnostic Directive (IVDD).
Biofortuna can offer over 40 years of experience in complex molecular diagnostics and are actively seeking collaborative partners for the development of new and bespoke products. Please feel free to contact us regarding possible collaborations, in-licensing or out-licensing opportunities.
"History shows us that HLA genotyping has always been in the vanguard of clinical genotyping; one of the first PCR-based genotyping applications used in clinical laboratory science was applied to HLA genotyping. Genotyping for transplantation is getting evermore complicated with hundreds of new allelic variants being identified every year: Biofortuna aim to produce products that simplify the HLA genotyping experience and apply those techniques in other genotyping applications."
Dr Mike Bunce
CEO Biofortuna